Vault-13

5AM Venture Management, LLC

SAN FRANCISCO, CA · CIK 1799883 · 13F filing filed 2024-08-14

SEC-registered investment adviser since 2021 · limited liability company

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
San Francisco, CA (main office)United States United Statesabout 8
Boston, MAUnited States United States7
New York, NYUnited States United States3

US visa salary filings

Job titleFilingsMedianRange
Senior Research AnalystNew York, NY 1 $350,000

Source: US Department of Labor, Labor Condition Application disclosure data (certified, full-time, yearly equivalent). These are the salaries the employer committed to pay the visa roles it filed for, at least the prevailing wage for the job and place; they are not the pay of all its staff. Filed by: 5AM Venture Management, LLC.

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$447.1m reported value +0.1% vs Q1 2024
28positions
73.5%in top 10
5 new 1 added 2 reduced 3 sold out vs Q1 2024

Holdings, Q2 2024

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 SKYE BIOSCIENCE INC COM NEW COM NEW 10,179,505 $81.5m18.24% 18.24% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 10.2m
2 ENTRADA THERAPEUTICS INC COM TRDA TRDA 4,408,379 $62.8m14.05% 14.05% UnchangedShares held: Q3 2023 4.4m, Q4 2023 4.4m, Q1 2024 4.4m, Q2 2024 4.4m
3 ENLIVEN THERAPEUTICS INC COM ELVN ELVN 2,610,875 $61.0m13.65% 13.65% ReducedShares held: Q3 2023 5.2m, Q4 2023 5.2m, Q1 2024 3.8m, Q2 2024 2.6m -1.2m -1,225,100 -31.9%
4 DIANTHUS THERAPEUTICS INC COM DNTH DNTH 1,232,965 $31.9m7.14% 7.14% ReducedShares held: Q3 2023 1.5m, Q4 2023 1.5m, Q1 2024 1.2m, Q2 2024 1.2m -9.1k -9,064 -0.7%
5 CELLDEX THERAPEUTICS INC NEW COM NEW CLDX CLDX 497,270 $18.4m4.12% 4.12% UnchangedShares held: Q3 2023 310.3k, Q4 2023 497.3k, Q1 2024 497.3k, Q2 2024 497.3k
6 BIOHAVEN LTD COM BHVN BHVN 469,972 $16.3m3.65% 3.65% AddedShares held: Q3 2023 0, Q4 2023 400.0k, Q1 2024 320.0k, Q2 2024 470.0k +150.0k +150,000 46.9%
7 TYRA BIOSCIENCES INC COM TYRA TYRA 939,298 $15.0m3.36% 3.36% UnchangedShares held: Q3 2023 411.4k, Q4 2023 555.0k, Q1 2024 939.3k, Q2 2024 939.3k
8 PHARVARIS N V COM PHVS PHVS 797,600 $15.0m3.35% 3.35% UnchangedShares held: Q3 2023 587.6k, Q4 2023 797.6k, Q1 2024 797.6k, Q2 2024 797.6k
9 PRAXIS PRECISION MEDICINES I COM NEW PRAX PRAX 340,000 $14.1m3.15% 3.15% UnchangedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 340.0k, Q2 2024 340.0k
10 ERASCA INC COM ERAS ERAS 5,405,404 $12.8m2.85% 2.85% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 5.4m
11 VIKING THERAPEUTICS INC COM VKTX VKTX 237,560 $12.6m2.82% 2.82% UnchangedShares held: Q3 2023 585.0k, Q4 2023 585.0k, Q1 2024 237.6k, Q2 2024 237.6k
12 MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD MLTX MLTX 282,313 $12.4m2.78% 2.78% UnchangedShares held: Q3 2023 313.2k, Q4 2023 302.6k, Q1 2024 282.3k, Q2 2024 282.3k
13 CENTESSA PHARMACEUTICALS PLC SPONSORED ADS SPONSORED ADS 1,245,000 $11.2m2.51% 2.51% UnchangedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 1.2m, Q2 2024 1.2m
14 TECTONIC THERAPEUTIC INC COM TECX TECX 646,524 $10.6m2.38% 2.38% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 646.5k
15 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 736,595 $9.6m2.14% 2.14% UnchangedShares held: Q3 2023 410.0k, Q4 2023 586.6k, Q1 2024 736.6k, Q2 2024 736.6k
16 SILENCE THERAPEUTICS PLC ADS SLN SLN 476,200 $9.0m2.02% 2.02% UnchangedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 476.2k, Q2 2024 476.2k
17 ANAPTYSBIO INC COM ANAB ANAB 357,733 $9.0m2.01% 2.01% UnchangedShares held: Q3 2023 357.7k, Q4 2023 357.7k, Q1 2024 357.7k, Q2 2024 357.7k
18 GH RESEARCH PLC ORDINARY SHARES GHRS GHRS 572,665 $6.7m1.49% 1.49% UnchangedShares held: Q3 2023 404.4k, Q4 2023 404.4k, Q1 2024 572.7k, Q2 2024 572.7k
19 COGENT BIOSCIENCES INC COM COGT COGT 790,440 $6.7m1.49% 1.49% UnchangedShares held: Q3 2023 790.4k, Q4 2023 790.4k, Q1 2024 790.4k, Q2 2024 790.4k
20 VOR BIOPHARMA INC COM COM 6,361,723 $6.4m1.42% 1.42% UnchangedShares held: Q3 2023 6.4m, Q4 2023 6.4m, Q1 2024 6.4m, Q2 2024 6.4m
21 SCPHARMACEUTICALS INC COM SCPH SCPH 1,200,647 $5.2m1.17% 1.17% UnchangedShares held: Q3 2023 1.2m, Q4 2023 1.2m, Q1 2024 1.2m, Q2 2024 1.2m
22 RALLYBIO CORP COM COM 3,630,724 $4.9m1.09% 1.09% UnchangedShares held: Q3 2023 3.6m, Q4 2023 3.6m, Q1 2024 3.6m, Q2 2024 3.6m
23 Q32 BIO INC COM QTTB QTTB 251,994 $4.5m1.01% 1.01% UnchangedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 252.0k, Q2 2024 252.0k
24 ADVERUM BIOTECHNOLOGIES INC COM NEW ADVM ADVM 541,666 $3.7m0.83% 0.83% UnchangedShares held: Q3 2023 0, Q4 2023 0, Q1 2024 541.7k, Q2 2024 541.7k
25 MERSANA THERAPEUTICS INC COM COM 1,305,000 $2.6m0.59% 0.59% UnchangedShares held: Q3 2023 1.3m, Q4 2023 1.3m, Q1 2024 1.3m, Q2 2024 1.3m
26 ZENTALIS PHARMACEUTICALS INC COM ZNTL ZNTL 490,000 $2.0m0.45% 0.45% UnchangedShares held: Q3 2023 490.0k, Q4 2023 490.0k, Q1 2024 490.0k, Q2 2024 490.0k
27 CIDARA THERAPEUTICS INC COM NEW CDTX CDTX 56,725 $677.3k0.15% 0.15% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 56.7k
28 EYEPOINT PHARMACEUTICALS INC COM NEW EYPT EYPT 50,000 $435.0k0.10% 0.10% NewShares held: Q3 2023 0, Q4 2023 0, Q1 2024 0, Q2 2024 50.0k

Sold out since Q1 2024

SecurityTickerShares held beforeValue then
MERUS N V MRUS MRUS 548,825 $24.7m548.8k shares
AVIDITY BIOSCIENCES INC RNA RNA 665,555 $17.0m665.6k shares
CIDARA THERAPEUTICS INC 1,134,511 $1.0m1.1m shares